1.
Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.
2.
3.
4.
5.
Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.
Implementation of indication-based pricing (10 th scenario) for daratumumab and pembrolizumab.
Input parameters for the base-case analysis.
Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.
Residential separation of capital groups.
Age profile of capital groups.
The Netherlands: Developments, institutions and policy-making.
List of survey items.
Educational homogamy and absence of intergenerational mobility.